A Method for Phenylalanine Self-monitoring Using Phenylalanine Ammonia-lyase and a Pre-existing Portable Ammonia Detection System

Overview

Journal Mol Genet Metab Rep

Specialty Endocrinology

Date 2023 Apr 6

PMID 37020603

Authors

Yoichi Wada

Eriko Totsune

Yasuko Mikami-Saito

Atsuo Kikuchi

Toshio Miyata

Shigeo Kure

Affiliations

Soon will be listed here.

Abstract

Phenylketonuria is an inborn error of phenylalanine metabolism caused by a phenylalanine hydroxylase deficiency. To prevent the occurrence of neurological symptoms and maternal complications resulting from phenylketonuria, patients must adhere to a strict diet therapy, tetrahydrobiopterin supplementation, or pegvaliase injection to maintain blood phenylalanine levels within a recommended range throughout their lives. Therefore, monitoring blood phenylalanine levels is necessary to determine the recent metabolic status of phenylalanine in patients with PKU; however, there are no available instruments for individuals to monitor their own blood phenylalanine levels using whole fingertip blood. We developed a phenylalanine monitoring system (designated as PheCheck) that included a pre-existing portable ammonia detection device and phenylalanine ammonia-lyase, which converts phenylalanine to trans-cinnamic acid and ammonia. This system was able to remove 86.7% ± 0.03% of the ammonia contained in fingertip blood and successfully reduce background ammonia levels. A good correlation was found between the estimated plasma phenylalanine levels detected by PheCheck and plasma phenylalanine levels detected by high-performance liquid chromatography (R 0.97). The entire PheCheck process for measuring blood phenylalanine takes only 20 min. PheCheck can lay the foundation for home phenylalanine monitoring with high feasibility because all the components are easily accessible. Further studies with a more user-friendly PheCheck optimized for practice are needed to improve blood phenylalanine control, reduce the burden on patients and/or caregivers, and prevent the sequelae associated with phenylketonuria.

Citing Articles

Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase.

Turgeon C, Casas K, Flanagan R, White A, Peck D, Pino G Mol Genet Metab Rep. 2024; 40:101110.

PMID: 39022300 PMC: 11252920. DOI: 10.1016/j.ymgmr.2024.101110.

Revealing Medicinal Constituents of Based on Non-Targeted Metabolomics and 16S rDNA Gene Sequencing Technology.

He H, Tang C, Cao Z, Wang T, He M, Xiao M Molecules. 2024; 29(4).

PMID: 38398612 PMC: 10892765. DOI: 10.3390/molecules29040860.

Fully Integrated Point-of-Care Platform for the Self-Monitoring of Phenylalanine in Finger-Prick Blood.

Messina M, Maugeri L, Spoto G, Puccio R, Ruggieri M, Petralia S ACS Sens. 2023; 8(11):4152-4160.

PMID: 37890867 PMC: 10683505. DOI: 10.1021/acssensors.3c01384.

Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with Phenylketonuria.

Rocha J, Ahring K, Bausell H, Bilder D, Harding C, Inwood A Nutrients. 2023; 15(18).

PMID: 37764724 PMC: 10536918. DOI: 10.3390/nu15183940.

References

Wada Y, Kikuchi A, Arai-Ichinoi N, Sakamoto O, Takezawa Y, Iwasawa S . Biallelic GALM pathogenic variants cause a novel type of galactosemia. Genet Med. 2018; 21(6):1286-1294. DOI: 10.1038/s41436-018-0340-x. View

Barros J, Dixon R . Plant Phenylalanine/Tyrosine Ammonia-lyases. Trends Plant Sci. 2019; 25(1):66-79. DOI: 10.1016/j.tplants.2019.09.011. View

Qi Y, Patel G, Henshaw J, Gupta S, Olbertz J, Larimore K . Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria. Clin Transl Sci. 2021; 14(5):1894-1905. PMC: 8504851. DOI: 10.1111/cts.13043. View

Longo N, Harding C, Burton B, Grange D, Vockley J, Wasserstein M . Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014; 384(9937):37-44. PMC: 4447208. DOI: 10.1016/S0140-6736(13)61841-3. View

Trefz F, van Spronsen F, MacDonald A, Feillet F, Muntau A, Belanger-Quintana A . Management of adult patients with phenylketonuria: survey results from 24 countries. Eur J Pediatr. 2014; 174(1):119-27. DOI: 10.1007/s00431-014-2458-4. View

Kure S, Hou D, Ohura T, Iwamoto H, Suzuki S, Sugiyama N . Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr. 1999; 135(3):375-8. DOI: 10.1016/s0022-3476(99)70138-1. View

Bilginsoy C, Waitzman N, Leonard C, Ernst S . Living with phenylketonuria: perspectives of patients and their families. J Inherit Metab Dis. 2005; 28(5):639-49. DOI: 10.1007/s10545-005-4478-8. View

Idili A, Parolo C, Ortega G, Plaxco K . Calibration-Free Measurement of Phenylalanine Levels in the Blood Using an Electrochemical Aptamer-Based Sensor Suitable for Point-of-Care Applications. ACS Sens. 2019; 4(12):3227-3233. PMC: 8097980. DOI: 10.1021/acssensors.9b01703. View

Cochrane F, Davin L, Lewis N . The Arabidopsis phenylalanine ammonia lyase gene family: kinetic characterization of the four PAL isoforms. Phytochemistry. 2004; 65(11):1557-64. DOI: 10.1016/j.phytochem.2004.05.006. View

10.

Rose A, Grosse S, Garcia S, Bach J, Kleyn M, Simon N . The financial and time burden associated with phenylketonuria treatment in the United States. Mol Genet Metab Rep. 2019; 21:100523. PMC: 6807265. DOI: 10.1016/j.ymgmr.2019.100523. View

11.

Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder D . Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. Genet Med. 2018; 21(8):1851-1867. PMC: 6752676. DOI: 10.1038/s41436-018-0403-z. View

12.

Dashtian K, Hajati S, Ghaedi M . L-phenylalanine-imprinted polydopamine-coated CdS/CdSe n-n type II heterojunction as an ultrasensitive photoelectrochemical biosensor for the PKU monitoring. Biosens Bioelectron. 2020; 165:112346. DOI: 10.1016/j.bios.2020.112346. View

13.

Ferreira B, Rodrigues M, Streck E, Ferreira G, Schuck P . White matter disturbances in phenylketonuria: Possible underlying mechanisms. J Neurosci Res. 2020; 99(1):349-360. DOI: 10.1002/jnr.24598. View

14.

Peterson K, Slover R, Gass S, Seltzer W, McCabe L, McCabe E . Blood phenylalanine estimation for the patient with phenylketonuria using a portable device. Biochem Med Metab Biol. 1988; 39(1):98-104. DOI: 10.1016/0885-4505(88)90063-1. View

15.

Moat S, Schulenburg-Brand D, Lemonde H, Bonham J, Weykamp C, Mei J . Performance of laboratory tests used to measure blood phenylalanine for the monitoring of patients with phenylketonuria. J Inherit Metab Dis. 2019; 43(2):179-188. PMC: 7957320. DOI: 10.1002/jimd.12163. View

16.

Jaulent P, Charriere S, Feillet F, Douillard C, Fouilhoux A, Thobois S . Neurological manifestations in adults with phenylketonuria: new cases and review of the literature. J Neurol. 2019; 267(2):531-542. DOI: 10.1007/s00415-019-09608-2. View

17.

Jurecki E, Cederbaum S, Kopesky J, Perry K, Rohr F, Sanchez-Valle A . Adherence to clinic recommendations among patients with phenylketonuria in the United States. Mol Genet Metab. 2017; 120(3):190-197. DOI: 10.1016/j.ymgme.2017.01.001. View

18.

Bell S, Wendt D, Zhang Y, Taylor T, Long S, Tsuruda L . Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria. PLoS One. 2017; 12(3):e0173269. PMC: 5345807. DOI: 10.1371/journal.pone.0173269. View

19.

Vockley J, Andersson H, Antshel K, Braverman N, Burton B, Frazier D . Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014; 16(2):188-200. DOI: 10.1038/gim.2013.157. View

20.

Levy H . Robert Guthrie and the Trials and Tribulations of Newborn Screening. Int J Neonatal Screen. 2021; 7(1). PMC: 7838808. DOI: 10.3390/ijns7010005. View